Palatin Technologies Inc
LSE:0KF3
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.3464
5.4491
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Realty Income Corp
NYSE:O
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one 0KF3 stock under the Base Case scenario is 0.1329 USD. Compared to the current market price of 1.6204 USD, Palatin Technologies Inc is Overvalued by 92%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Palatin Technologies Inc
Run backtest to discover the historical profit from buying and selling 0KF3 based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
![](https://ik.imagekit.io/kkbzr2uz4cp/other/ai-assistant.png)
Palatin Technologies Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies to address unmet medical needs in various health conditions, particularly in women's health and sexual dysfunction. The company is primarily known for its lead product candidate, Vyleesi (bremelanotide injection), which was approved by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). This groundbreaking therapy offers a novel approach to a condition that has traditionally been underserved, highlighting Palatin’s commitment to improving quality of life for its patients. With a robust pipeline of other potential treatments, the c...
Palatin Technologies Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies to address unmet medical needs in various health conditions, particularly in women's health and sexual dysfunction. The company is primarily known for its lead product candidate, Vyleesi (bremelanotide injection), which was approved by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). This groundbreaking therapy offers a novel approach to a condition that has traditionally been underserved, highlighting Palatin’s commitment to improving quality of life for its patients. With a robust pipeline of other potential treatments, the company is positioning itself to be a significant player in the biotech sector.
Investors will find Palatin appealing not only for its unique product offerings but also for its strategic partnerships and collaborations that enhance its research capabilities and market reach. The company has established relationships with key healthcare organizations, enabling it to conduct pivotal clinical trials and expand its product visibility. Additionally, leadership at Palatin utilizes a disciplined, value-investing approach, ensuring that resources are allocated wisely towards projects with solid scientific backing and commercial potential. As the company advances its portfolio, it aims to create long-term shareholder value while addressing critical areas of health, making it a compelling opportunity for those looking to invest in the future of biopharmaceutical innovations.
Palatin Technologies, Inc. is a biopharmaceutical company primarily focused on developing innovative therapies based on its proprietary peptide technology. The core business segments of Palatin Technologies can generally be categorized as follows:
-
Pharmaceutical Development:
- Therapeutic Areas: The company primarily focuses on addressing condition in sexual health, alongside other potential indications. This includes treatments for erectile dysfunction and female sexual dysfunction.
- Clinical Trials: Palatin engages in various stages of clinical development, conducting trials to validate the efficacy and safety of its drug candidates.
-
Drug Pipeline:
- Palatin's drug pipeline includes potential treatments that leverage its proprietary technologies. For example, its lead drug candidate has attracted attention for its potential in treating specific disorders related to sexual function.
- The company may also explore new indications for its existing drug candidates, expanding its market potential.
-
Partnerships and Collaborations:
- Palatin often engages in partnerships with larger pharmaceutical companies for co-development, marketing, or licensing of its drug candidates. These collaborations can help fund further research and development and facilitate market access.
-
Regulatory Affairs:
- The company is focused on navigating the regulatory landscape required for the approval of its drug candidates by bodies such as the U.S. Food and Drug Administration (FDA). This includes preparation for clinical trials, submissions for new drug applications (NDAs), and ongoing regulatory compliance.
-
Commercialization and Marketing:
- If successful in obtaining regulatory approval, Palatin would look to commercialize its products, which involves strategic marketing initiatives and potentially distribution agreements to reach the target markets effectively.
These segments illustrate Palatin Technologies’ strategic focus on advancing its pipeline of biopharmaceutical products and negotiating the complexities of drug development and commercialization in the healthcare industry.
Palatin Technologies Inc. has several unique competitive advantages that may differentiate it from its rivals in the biotechnology and pharmaceutical sectors:
-
Niche Focus on Melanocortin Receptors: Palatin specializes in targeting melanocortin receptors, particularly its lead product candidate, PL8177, for the treatment of conditions like gastrointestinal disorders. This focus allows for specialized knowledge and development expertise, creating a barrier to entry for competitors.
-
Strong Intellectual Property Portfolio: The company has an established portfolio of patents and proprietary technologies that provide protection for its products and methods, enhancing its competitive position and making it more difficult for others to replicate its innovations.
-
Clinical Development Stage: As a company engaged in clinical trials, Palatin has the opportunity to conduct thorough R&D, which can lead to valuable data and insights that strengthen its product offerings. Successful clinical results can improve market positioning and investor confidence.
-
Collaboration and Partnerships: Palatin has formed strategic partnerships and collaborations with larger pharmaceutical companies, which can provide additional resources, funding, and market access, enabling it to leverage the strengths of partners while reducing its own financial risks.
-
Expertise in Drug Development: The leadership team’s experience and expertise in drug development and commercialization can contribute to the successful navigation of the regulatory landscape, leading to quicker and more efficient paths to market.
-
Targeted Therapeutics for Underserved Markets: Palatin is focused on developing therapies for conditions that are often overlooked or underserved by larger pharmaceutical companies, potentially allowing it to capture a dedicated market segment with less competition.
-
Clinical and Preclinical Pipeline: A robust pipeline of drug candidates can provide multiple avenues for growth and revenue generation, spreading risk among various projects and increasing the likelihood of commercial success for at least some products.
While these advantages contribute to its competitive positioning, the biotechnology field is inherently risky, and continuous innovation, adaptability, and successful execution will be crucial for Palatin's long-term success.
Palatin Technologies Inc. (PTN), a biopharmaceutical company primarily focused on developing and commercializing targeted therapies for various medical conditions, faces several risks and challenges. Here are some key factors to consider:
-
Clinical Development Risks:
- Clinical Trial Outcomes: The success of their drug candidates depends heavily on clinical trial results. Negative outcomes can significantly impact the company's valuation and future prospects.
- Regulatory Approval: Navigating the regulatory landscape is complex, and there is no guarantee that the FDA or other regulatory bodies will approve new drugs, which can halt progress or lead to delays.
-
Financing and Funding:
- Capital Requirements: Research and development in the biopharmaceutical industry are capital-intensive. Palatin may face challenges in securing enough funding to sustain operations and complete clinical trials.
- Stock Market Vulnerability: As a publicly-traded company, stock performance can be volatile, which may impact their ability to raise funds through equity markets.
-
Market Competition:
- Competing Products: The pharmaceutical industry is highly competitive, with many companies developing similar therapies. New entrants and existing companies with better-funded resources can threaten Palatin's market position.
- Pricing Pressures: Government and public scrutiny regarding drug pricing can impact profitability, especially for newer therapies.
-
Intellectual Property Risks:
- Patent Protection: Maintaining and defending intellectual property rights is crucial. If their patents are challenged or they fail to secure patent protection, it may lead to loss of competitive advantage.
- Infringement Risks: There is always a risk of infringement on other companies' patents, which could lead to costly litigation.
-
Market Adoption:
- Healthcare Provider Acceptance: Even with successful clinical trials, gaining acceptance from healthcare providers is critical for commercial success. Resistance from physicians and payers can hinder market penetration.
- Patient Adherence: Ensuring that patients adhere to prescribed therapies is essential for the commercial success of their products.
-
Economic and Regulatory Changes:
- Healthcare Policy Changes: Changes in healthcare regulations or policies, including healthcare reforms, can impact market access and reimbursement landscapes.
- Economic Downturns: Economic factors and downturns can affect funding, investor interest, and overall market conditions, impacting operations and growth.
-
Operational Risks:
- Supply Chain Challenges: Disruptions in the supply chain, whether due to geopolitical factors, pandemics, or other issues, can affect manufacturing and distribution.
- Management Execution: The ability of the management team to effectively execute on business strategies is crucial. Poor operational decisions can lead to inefficiencies and missed opportunities.
In summary, Palatin Technologies faces a complex array of risks and challenges that can impact its growth trajectory and market performance in the near future. Addressing these risks through strategic planning and operational excellence will be crucial for the company’s success.
Revenue & Expenses Breakdown
Palatin Technologies Inc
Balance Sheet Decomposition
Palatin Technologies Inc
Current Assets | 10.3m |
Cash & Short-Term Investments | 10m |
Other Current Assets | 254.6k |
Non-Current Assets | 1.1m |
PP&E | 1.1m |
Other Non-Current Assets | 56.9k |
Current Liabilities | 8.5m |
Accounts Payable | 3.4m |
Accrued Liabilities | 2.7m |
Other Current Liabilities | 2.4m |
Non-Current Liabilities | 1.3m |
Other Non-Current Liabilities | 1.3m |
Earnings Waterfall
Palatin Technologies Inc
Revenue
|
5.9m
USD
|
Cost of Revenue
|
-197.6k
USD
|
Gross Profit
|
5.7m
USD
|
Operating Expenses
|
-38.5m
USD
|
Operating Income
|
-32.8m
USD
|
Other Expenses
|
-106.2k
USD
|
Net Income
|
-32.9m
USD
|
Free Cash Flow Analysis
Palatin Technologies Inc
USD | |
Free Cash Flow | USD |
In the third quarter of FY2024, Palatin reported a significant operational shift following the sale of Vyleesi's rights, resulting in zero product sales for the quarter, down from $3.4 million in Q3 FY2023. Operating expenses rose to $9.2 million, primarily due to increased investment in melanocortin receptor programs. The net loss narrowed to $8.4 million from $8.7 million. Key developments included promising Phase III results for PL-9643 in treating dry eye disease, with plans to initiate two new clinical programs by mid-2024. The company's cash position improved to $10 million, projecting sufficient funds into the second half of calendar 2024.
What is Earnings Call?
0KF3 Profitability Score
Profitability Due Diligence
Palatin Technologies Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Palatin Technologies Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
0KF3 Solvency Score
Solvency Due Diligence
Palatin Technologies Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Palatin Technologies Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
0KF3 Price Targets Summary
Palatin Technologies Inc
According to Wall Street analysts, the average 1-year price target for 0KF3 is 8.7252 USD with a low forecast of 2.9906 USD and a high forecast of 17.6182 USD.
Shareholder Yield
Current shareholder yield for 0KF3 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
0KF3 Price
Palatin Technologies Inc
Average Annual Return | 153.22% |
Standard Deviation of Annual Returns | 267.85% |
Max Drawdown | -83% |
Market Capitalization | 44.5B USD |
Shares Outstanding | 27 468 700 139 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The company is headquartered in Cranbury, New Jersey and currently employs 26 full-time employees. Palatin is focused on developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Palatin product candidates are targeted receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions and tissue homeostasis, and therapeutic agents modulating this system have potential to treat cardiovascular and fibrotic diseases. Palatin lead product includes Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Its other product line includes PL9643 for dry eye disease and anti-inflammatory ocular indications and Oral PL8177 for inflammatory bowel diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one 0KF3 stock under the Base Case scenario is 0.1329 USD.
Compared to the current market price of 1.6204 USD, Palatin Technologies Inc is Overvalued by 92%.